FDA Votes in Favor of Peptides After Lengthy Deliberation

An FDA advisory panel voted for the approval of 4 peptides in a thin margin on Thursday, opening the door for access to BPC-157, TB-500, MOTS-c, and KPV following the FDA’s future sign-off.¹ In what sources are calling a “highly unusual move,” these 4 substances, despite still being on the path of a prolonged regulatory process, may now be showing up in pharmacy counters across the country.²

Debates surrounding peptide use flooded the headlines throughout 2026, all leading to the FDA’s July 23 and 24 advisory committee meeting.

What This Vote Could Mean

With several proponents and detractors of peptide use expressing their vocalism as of late, the first part of the FDA hearing saw a collection of 24 speakers, 4 of whom were scientists against peptide use, and the other 20 represented physicians, chemists, and stakeholders in the peptide market. Following the panel’s 8-6 vote in favor of the 4 peptides, it’s clear to see that the aisle is split regarding the safety of these formulations among US patients.¹

“I voted yes because it’s time to put this decision back in the hands of the patient, the physician, and the pharmacist,” David Pope, chief pharmacy officer of Xifin Pharmacy Solutions and supporter of BPC-157, said to NBC4 Washington.³ Another panelist, Elizabeth Rebello, MD, FASA, from the University of Texas MD Anderson Center, said, “I’m concerned we’re responding to a market-induced demand rather than a decision based in solid science.”

READ MORE: FDA Panel to Evaluate 7 Popular Peptides for Compounding Substances List

This regulatory shift marks a significant departure from the FDA’s 2023 stance, when the agency essentially prohibited compounding pharmacies from dispensing these substances, citing that they “may present significant safety risks” due to a lack of testing.^1,2

Although the panel's vote is not binding, it is expected to embolden US Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., a vocal proponent of peptides who has vowed to overturn previous restrictions.^3,4

What This Could Mean for Pharmacists

For pharmacists, this decision creates a complex professional landscape.

The American Pharmacists Association (APhA) has expressed deep concern, urging the FDA to prioritize scientific evidence over market trends. Brigid Groves, PharmD, MS, vice president of professional affairs at APhA, emphasized that although pharmacists value innovation, it must be grounded in patient safety, particularly when patients are turning to unregulated online gray markets for products of unknown quality.⁵

The gray market remains a primary driver for the panel’s recommendation. Advocates, including telehealth companies that saw stock prices rise following the vote, argue that allowing 503A compounding pharmacies to dispense these peptides provides a safer alternative to unvetted imports from foreign suppliers.^2,4

Scott Brunner, CEO of the Alliance for Pharmacy Compounding, suggested that creating a lawful pathway through state-licensed pharmacies would allow for better oversight, including mandatory adverse event reporting and the use of FDA-registered wholesalers.⁴

However, critics like Peter Lurie, MD, MPH, president of the Center for Science in the Public Interest, warn that this move removes the incentive for companies to pursue rigorous clinical trials, potentially leaving pharmacists without the data necessary to ensure long-term efficacy.^1,2,4

Despite mainstay peptides like insulin and glucagon-like peptide-1 medications being supported by thousands of human trials, unapproved peptides like BPC-157 have often been tested on fewer than 50 people. Rita Jew, PharmD, MBA, BCPPS, FASHP, president of the Institute for Safe Medication Practices, described the situation as “alarming,” noting the rarity of substances being injected by patients with such a profound lack of clinical evidence.^1,3

As the hearing continues into its second day, the committee is scheduled to deliberate on 3 additional peptides: emideltide, epitalon, and semax. If the FDA follows the panel’s recommendation, it could lead to a temporary policy reassuring pharmacies that they will not be targeted for compounding these substances while a formal rulemaking process, which can take years, begins.^3,4

In the interim, legal experts suggest that the future of peptide regulation may mirror that of dietary supplements, where the FDA primarily intervenes only after harm is demonstrated. For now, pharmacists are left to navigate a “wild west” environment where consumer demand is rapidly outpacing traditional regulatory safeguards.

“Patients are getting what purport to be these substances, or are using drugs that are made with research-grade active ingredients, and I almost expect any day now there’s going to be some serious patient adverse event or a series of patients who are made ill or worse by taking batches of these drugs that were not made to FDA standards or with active ingredients that are not made to FDA standards,” Brunner said to CNN Health.⁴

READ MORE: Q&A: Understanding the Pharmaceutical Community’s Attention on Peptides

REFERENCES

1. Breen K, Yamaguchi A. FDA panel recommends loosening regulations for some peptides amid surge in interest. CBS News. July 24, 2026. Accessed July 24, 2026. https://www.cbsnews.com/news/fda-peptides-review-regulations-unapproved-therapies/

2. Semuels A. An FDA committee just voted in favor of Peptides—despite the agency’s opposition. TIME. July 24, 2026. Accessed July 24, 2026. https://time.com/article/2026/07/23/fda-committee-peptides/

3. Perrone M. FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. NBC4 Washington. July 24, 2026. Accessed July 24, 2026. https://www.nbcwashington.com/news/national-international/fda-panel-narrowly-backs-peptide-drugs-rfk-jr/4133757/

4. Howard J. The future of peptides in the US is about to become clearer. Here’s what you should know. CNN Health. July 23, 2026. Accessed July 24, 2026. https://www.cnn.com/2026/07/22/health/peptides-fda-compounding-pharmacies-meeting-wellness

5. APhA urges FDA to put patient safety first in review of peptide substances. News Release. American Pharmacists Association. July 17, 2026. Accessed July 24, 2026. https://www.pharmacist.com/APhA-Press-Releases/apha-urges-fda-to-put-patient-safety-first-in-review-of-peptide-substances